SBBC:CA:TSV-Simply Better Brands Corp (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.35

Change

0.00 (0.00)%

Market Cap

USD 0.03B

Volume

7.50K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-22 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

N/A

USD 0.10B
LOVE:CA Cannara Biotech Inc

-0.03 (-3.61%)

USD 0.08B
ZYUS:CA ZYUS Life Sciences Corporation

N/A

USD 0.07B
DB:CA Decibel Cannabis Company Inc

N/A

USD 0.05B
LSL:CA LSL Pharma Group Inc.

N/A

USD 0.04B
PCLO:CA Pharmacielo Ltd

-0.01 (-5.41%)

USD 0.03B
ROMJ:CA Rubicon Organics Inc

+0.01 (+1.37%)

USD 0.02B
ELXR:CA Elixxer Ltd

N/A

USD 0.01B
NDVA:CA Indiva Ltd

N/A

USD 0.01B
DHB:CA Delivra Health Brands Inc.

N/A

USD 0.01B

ETFs Containing SBBC:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 59.09% 82% B 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.09% 82% B 86% B+
Trailing 12 Months  
Capital Gain -30.00% 55% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.00% 55% F 50% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -34.35% 19% F 5% F
Dividend Return -34.35% 19% F 5% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.95% 57% F 52% F
Risk Adjusted Return -76.43% 29% F 18% F
Market Capitalization 0.03B 73% C 75% C

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.